A linezolid prior authorization program: Clinical and economic outcomes

American Journal of Pharmacy Benefits

Volumn 6, Issue 2, 2014, Pages 81-88

  Starner, Catherine I ^a,b   Scott Mcclelland, R ^c   Qiu, Yang ^a   Zabinski, Richard A ^a   Cotter, Nancy ^c   Gleason, Patrick P ^a,b  

^a Prime Therapeutics LLC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Florida Blue   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ARTICLE; COMPARATIVE STUDY; DRUG COST; ECONOMIC ASPECT; EMERGENCY WARD; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCOME; MALE; OUTCOME ASSESSMENT; PHARMACY; POLICY; PRESCRIPTION; PRIOR AUTHORIZATION POLICY; QUASI EXPERIMENTAL STUDY; SENSITIVITY ANALYSIS;

EID: 84898788555     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pharmacy Benefit Management Institute. 2012-2013 Prescription Drug Benefit Cost and Plan Design Online Report. http://www.benefitdesignreport.com/ Accessed May 23, 2013.
2. Academy of Managed Care Pharmacy. Managed Care Terms. http://amcp.org/ManagedCareTerms. Accessed May 15, 2013.
3. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;7(4):297-302.
4. Fallik B. The Academy of Managed Care Pharmacy's concepts in managed care pharmacy: prior authorization and the formulary exception process. J Manag Care Pharm. 2005;11:358-361.
5. Shoemaker SJ, Pozniak A, Subramanian R, et al. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2010;16:S1-S20.
6. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care. 2010;48:4-9.
7. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15:648-658.
8. Ball AT, Xu Y, Sanchez RJ, Shelbaya A, Deminski MC, Nau DP. Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Clin Ther. 2010;32(13):2246-2256.
9. Pasquale MK, Louder AM, Deminski MC, Chambers RB, Haider S. Out-of-pocket costs and prescription reversals: the case of oral linezolid. Poster presented at AMCP annual meeting; April 5, 2013; San Diego, CA. J Manag Care Pharm. 2013;19:182.
10. Zyvox (linezolid) prescribing information. New York, NY: Pharmacia & Upjohn Co, division of Pfizer Inc; 2013.
11. Hicks LA, Taylor TH, Hunkler RJ. U.S. Outpatient Antibiotic Prescribing, 2010 [letter]. N Engl J Med. 2013;368(15):1461-1462.
12. Office-related antibiotic prescribing for persons aged <14 years - United States, 1993-1994 to 2007-2008. Morb Mortal Wkly Rep. 2011;60:1153-1156.
13. FDA alert: information for healthcare professionals: linezolid (marketed as Zyvox). US Food and Drug Administration website. http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ ucm085249.htm. Accessed May 22, 2013.
14. FDA drug safety communication: updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications. US Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ ucm276251.htm. Accessed May 22, 2013.
15. Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach [published online April 2, 2013]. Ann Pharmacother. 2013;47(4):543-560. doi:10.1345/aph.1R604.
16. US Department of Health and Human Services; Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. April 23, 2013;1-114. http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed November 4, 2013.
17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251.
18. National Cancer Institute. SEER-Medicare: Calculation of Comorbidity Weights. http://healthservices.cancer.gov/seermedicare/program/comorbidity.html.
19. DeNavas-Walt C, Proctor BD, Smith JC. US Census Bureau, Current Population Reports, P60-243, Income, Poverty, and Health Insurance Coverage in the United States: 2011. US Government Printing Office, Washington, DC; 2012.
20. Starner CI, Fenrick B, Coleman J, Wickersham P, Gleason PP. Rosiglita zone prior authorization safety policy: a cohort study. J Manag Care Pharm. 2012;18: 225-233.
21. Gleason PP, Phillips J, Fenrick BA, Delgado-Riley A, Starner CI. Dalfampridine prior authorization program: a cohort study. J Manag Care Pharm. 2013;19:18-25.
22. Bergeson JG, Worley K, Louder A, Ward M, Graham J. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. J Manag Care Pharm. 2013;19(5):374-384.
23. Walthour A, Seymour L, Tackett R, Perri M. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents. Ann Pharmacother. 2010;44:809-817